A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: a2d003fef430d2e5ad80ecf74a694dd8ab34aa2b
First added on: Feb 10, 2025